Syndax Pharmaceuticals, Inc. (SNDX) Operating cash flow 2016–2025
Syndax Pharmaceuticals, Inc. (SNDX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$323.0MFY2025 · since FY2016: -$35.2M → -$323.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$323.0M | -17.5% |
| FY2024 | -$274.9M | -71.2% |
| FY2023 | -$160.6M | -20.1% |
| FY2022 | -$133.7M | -558.9% |
| FY2021 | $29.1M | +140.9% |
| FY2020 | -$71.3M | -40.8% |
| FY2019 | -$50.6M | +26.1% |
| FY2018 | -$68.5M | -44.7% |
| FY2017 | -$47.4M | -34.7% |
| FY2016 | -$35.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SNDX financial trends
SNDX RevenueSNDX Net incomeSNDX Net marginSNDX Gross profitSNDX Gross marginSNDX Operating incomeSNDX Operating marginSNDX Free cash flowSNDX Capital expendituresSNDX Return on equitySNDX Stock buybacksSNDX Dividends paidSNDX Total assetsSNDX Total liabilitiesSNDX Shareholders’ equitySNDX overview →